ARTICLE | Company News
AstraZeneca sales and marketing update
June 27, 2016 7:00 AM UTC
Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that added benefit of Tagrisso osimertinib from AstraZeneca is “not proven” vs. comparator th...